RESUMEN
Scabies is one of the most common disorders identified in any estimate of global skin disease prevalence. Furthermore, quantifying its impact on individuals and societies has been problematic. There has been a lack of clear case definitions and laboratory tests. There have been few epidemiological studies, particularly those focusing on low-income countries, variation in prevalence within high-income countries, or estimates of the effect of scabies on health beyond the skin, such as renal disease or mental wellbeing. Economic studies are also lacking. However, the new strategy of integrating surveillance for skin Neglected Tropical Diseases may well produce advancements on these issues, in addition to providing an overarching structure for health improvement and disease control.
Asunto(s)
Escabiosis , Enfermedades de la Piel , Humanos , Prevalencia , Escabiosis/diagnóstico , Escabiosis/epidemiología , Escabiosis/prevención & control , PielRESUMEN
Tinea capitis is a fungal infection mostly affecting children. Epidemiology is changing over time due to migration, and it has been estimated that up to 40% of children from certain developing countries are affected. The mechanism of transmission is still unclear although asymptomatic carriage seems to have an influence in establishing persistent reservoirs that can cause or fuel epidemics. Screening and prophylactic treatment of close contacts of tinea capitis patients are therefore recommended by several international guidelines, but vaguely and not consistent. The treatments involved can be expensive, hard to integrate in everyday life, have well-known side effects and some are not approved for the treatment of children. The aim of this review was to clarify the evidence behind treatment of human asymptomatic carriers of tinea capitis. Databases were searched for the 'tinea capitis', 'carriers' and 'treatment'. Inclusion criteria were clinical trials, observational and interventional studies including case series (10+ cases) and case reports in English, Danish, Swedish, Norwegian and French. Reviews, guidelines, unclear reports and in vitro trials were excluded. A systematic review identified 10 studies with low to moderate evidence levels. The topical treatments ketoconazole, povidone-iodine, miconazole and the systemic antifungals terbinafine and itraconazole have all shown significant effects in the mycological eradication of fungal conidia. General prophylactic hygienic measures may have a benefit. The scientific evidence behind the treatment of asymptomatic carriage of scalp dermatophytes is sparse and not of high quality. Yet, both topical and systemic antifungal agents show treatment efficacy. Considering the possible adverse effects, topical agents are preferable, but with necessary attention to the compliance of asymptomatic contacts with treatment.
Asunto(s)
Naftalenos , Tiña del Cuero Cabelludo , Antifúngicos/uso terapéutico , Niño , Humanos , Itraconazol , Terbinafina , Tiña del Cuero Cabelludo/tratamiento farmacológico , Tiña del Cuero Cabelludo/epidemiologíaRESUMEN
BACKGROUND: Dermatophytosis is a world-wide distributed common infection. Antifungal drug resistance in dermatophytosis used to be rare, but unfortunately the current Indian epidemic of atypical widespread recalcitrant and terbinafine-resistant dermatophytosis is spreading and has sporadically been reported in Europe. OBJECTIVES: To explore the occurrence of clinical and mycological proven antifungal drug resistance in dermatophytes in Europe. METHODS: A standardized questionnaire was distributed through the EADV Task Force of Mycology network to dermatologists in Europe. RESULTS: Representatives from 20 countries completed the questionnaires of which 17 (85 %) had observed clinical and/or mycological confirmed antifungal resistance, two countries published cases of antifungal resistance and one country had no known cases. CONCLUSIONS: This pilot study confirms that both clinical and mycological antifungal resistance exist in Europe.
Asunto(s)
Antifúngicos , Tiña , Antifúngicos/uso terapéutico , Europa (Continente) , Humanos , Proyectos Piloto , Tiña/tratamiento farmacológico , Tiña/epidemiología , Insuficiencia del TratamientoRESUMEN
BACKGROUND: Scabies is a common parasitic skin condition that causes considerable morbidity globally. Clinical and epidemiological research for scabies has been limited by a lack of standardization of diagnostic methods. OBJECTIVES: To develop consensus criteria for the diagnosis of common scabies that could be implemented in a variety of settings. METHODS: Consensus diagnostic criteria were developed through a Delphi study with international experts. Detailed recommendations were collected from the expert panel to define the criteria features and guide their implementation. These comments were then combined with a comprehensive review of the available literature and the opinion of an expanded group of international experts to develop detailed, evidence-based definitions and diagnostic methods. RESULTS: The 2020 International Alliance for the Control of Scabies (IACS) Consensus Criteria for the Diagnosis of Scabies include three levels of diagnostic certainty and eight subcategories. Confirmed scabies (level A) requires direct visualization of the mite or its products. Clinical scabies (level B) and suspected scabies (level C) rely on clinical assessment of signs and symptoms. Evidence-based, consensus methods for microscopy, visualization and clinical symptoms and signs were developed, along with a media library. CONCLUSIONS: The 2020 IACS Criteria represent a pragmatic yet robust set of diagnostic features and methods. The criteria may be implemented in a range of research, public health and clinical settings by selecting the appropriate diagnostic levels and subcategories. These criteria may provide greater consistency and standardization for scabies diagnosis. Validation studies, development of training materials and development of survey methods are now required. What is already known about this topic? The diagnosis of scabies is limited by the lack of accurate, objective tests. Microscopy of skin scrapings can confirm the diagnosis, but it is insensitive, invasive and often impractical. Diagnosis usually relies on clinical assessment, although visualization using dermoscopy is becoming increasingly common. These diagnostic methods have not been standardized, hampering the interpretation of findings from clinical research and epidemiological surveys, and the development of scabies control strategies. What does this study add? International consensus diagnostic criteria for common scabies were developed through a Delphi study with global experts. The 2020 International Alliance for the Control of Scabies (IACS) Criteria categorize diagnosis at three levels of diagnostic certainty (confirmed, clinical and suspected scabies) and eight subcategories, and can be adapted to a range of research and public health settings. Detailed definitions and figures are included to aid training and implementation. The 2020 IACS Criteria may facilitate the standardization of scabies diagnosis.
Asunto(s)
Escabiosis , Administración Tópica , Consenso , Humanos , Escabiosis/diagnóstico , Escabiosis/epidemiología , PielRESUMEN
Cutaneous candidiasis is a common skin disease, and several treatments have been investigated within the last fifty years. Yet, systematic reviews are lacking, and evidence-based topical and systemic treatment strategies remain unclear. Thus, the aim of this review was to summarize efficacy and adverse effects of topical and oral therapies for cutaneous candidiasis in all age groups. Two individual researchers searched PubMed and EMBASE for 'cutaneous candidiasis' and 'cutaneous candidiasis treatment', 'intertrigo', 'diaper dermatitis' and 'cheilitis'. Searches were limited to 'English language', 'clinical trials' and 'human subjects', and prospective clinical trials published in abstracts or articles were included. In total, 149 studies were identified, of which 44 were eligible, comprising 41 studies of 19 topical therapies and four studies of three systemic therapies for cutaneous candidiasis. Topical therapies were investigated in infants, children, adolescents, adults and elderly, while studies of systemic therapies were limited to adolescents and adults. Clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated similar efficacy with complete cure rates of 73%-100%. Single-drug therapy was as effective as combinations of antifungal, antibacterial and topical corticosteroid. Four studies investigated systemic therapy, and oral fluconazole demonstrated similar efficacy to oral ketoconazole and topical clotrimazole. Limitations to this review were mainly that heterogeneity of studies hindered meta-analyses. In conclusions, clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated equal good efficacy and mild adverse effects similar to combinations of antifungal, antibacterial and topical corticosteroids. Oral fluconazole was as effective as topical clotrimazole and is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis Cutánea/tratamiento farmacológico , Clotrimazol/uso terapéutico , Fluconazol/uso terapéutico , Miconazol/uso terapéutico , Nistatina/uso terapéutico , Administración Oral , Administración Tópica , Antifúngicos/administración & dosificación , Clotrimazol/administración & dosificación , Quimioterapia Combinada , Medicina Basada en la Evidencia , Fluconazol/administración & dosificación , Humanos , Cetoconazol/uso terapéutico , Miconazol/administración & dosificación , Nistatina/administración & dosificaciónRESUMEN
BACKGROUND: Superficial fungal infections are common. It is important to confirm the clinical diagnosis by mycological laboratory methods before initiating systemic antifungal treatment, especially as antifungal sensitivity and in vitro susceptibility may differ between different genera and species. For many years, the gold standard for diagnosis of superficial fungal infections has been direct fungal detection in the clinical specimen (microscopy) supplemented by culturing. Lately, newer molecular based methods for fungal identification have been developed. OBJECTIVE: This study was initiated to focus on the current usage of mycological diagnostics for superficial fungal infections by dermatologists. It was designed to investigate whether it was necessary to differentiate between initial diagnostic tests and those used at treatment follow-up in specific superficial fungal infections. METHODS: An online questionnaire was distributed among members of the EADV mycology Task Force and other dermatologists with a special interest in mycology and nail disease. RESULTS: The survey was distributed to 62 dermatologists of whom 38 (61%) completed the whole survey, 7 (11%) partially completed and 17 (27%) did not respond. Nearly, all respondents (82-100%) said that ideally they would use the result of direct microscopy (or histology) combined with a genus/species directed treatment of onychomycosis, dermatophytosis, Candida- and Malassezia-related infections. The majority of the dermatologists used a combination of clinical assessment and direct microscopy for treatment assessment and the viability of the fungus was considered more important at this visit than when initiating the treatment. Molecular based methods were not available for all responders. CONCLUSION: The available diagnostic methods are heterogeneous and their usage differs between different practices as well as between countries. The survey confirmed that dermatologists find it important to make a mycological diagnosis, particularly prior to starting oral antifungal treatment in order to confirm the diagnose and target the therapy according to genus and species.
Asunto(s)
Antifúngicos/administración & dosificación , Dermatomicosis/diagnóstico , Onicomicosis/diagnóstico , Pautas de la Práctica en Medicina/tendencias , Encuestas y Cuestionarios , Comités Consultivos , Antifúngicos/farmacología , Dermatólogos , Dermatomicosis/tratamiento farmacológico , Dermatomicosis/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Onicomicosis/tratamiento farmacológico , Onicomicosis/microbiología , Medición de Riesgo , Resultado del TratamientoRESUMEN
Tinea capitis remains a common childhood infection in many parts of the world. Yet knowledge of the underlying pathogenetic mechanisms and the development of effective immunity have shown striking advances, and new methods of diagnosis ranging from dermoscopy to molecular laboratory tests have been developed even though they have not been assimilated into routine practice in many centres. Treatment is effective although it needs to be given for at least 1 month. What is missing, however, is a systematic approach to control through case ascertainment and therapy.
Asunto(s)
Tiña del Cuero Cabelludo/epidemiología , Tiña del Cuero Cabelludo/microbiología , Antifúngicos/uso terapéutico , Arthrodermataceae/clasificación , Arthrodermataceae/aislamiento & purificación , Pruebas Diagnósticas de Rutina/métodos , Salud Global , Humanos , Tiña del Cuero Cabelludo/diagnóstico , Tiña del Cuero Cabelludo/tratamiento farmacológicoAsunto(s)
Infecciones por Coronavirus , Exantema , Pandemias , Neumonía Viral , Betacoronavirus , COVID-19 , Consenso , Humanos , Estudios Prospectivos , SARS-CoV-2 , EspañaRESUMEN
From their original description, fungi of the genus Malassezia (previously Pityrosporum) have been associated with dandruff and seborrhoeic dermatitis. The principle evidence on which this connection was based was that the organisms were present, often in high numbers, on the skin in these conditions and that both responded to treatment that inhibited or destroyed Malassezia yeasts. The availability of new tools such as genomic and proteomic analyses has begun to provide a new insight into the pathogenetic mechanisms involved. New evidence shows the production of specific phospholipases on affected skin sites in dandruff and signalling molecules such as malassezin in seborrhoeic dermatitis. It is still not clear why those individuals and skin sites, prone to either disease, are particularly associated with the presence of these marker molecules but these studies are providing clues to the different ways in which organisms, which are normally commensals, interact with human skin.
Asunto(s)
Dermatitis Seborreica/microbiología , Dermatomicosis/microbiología , Malassezia , Dermatosis del Cuero Cabelludo/microbiología , Antifúngicos/uso terapéutico , Humanos , Tiña Versicolor/microbiologíaRESUMEN
Tracking the history of the discovery of mycetoma is not simple because identifying the roots of medical knowledge depends on utilising sources that employ imprecise and sometimes confusing descriptions when compared with those based on modern medical terminology. Ancient sources of information include writings, such as poetry, archaeology and paleopathology, as well as legend and folklore. The earliest precise descriptions of mycetoma were recorded in the mid-19th century by medical officers working in southern India. But interest in the disease spread rapidly both among doctors in India and elsewhere, from Algeria to Mexico to Sudan. Although over time the names of organisms have changed, the clinical and pathological descriptions still stand as testament to those early detailed studies. Some of the conclusions of the early investigators, particularly the general lack of effective treatment and the difficulty in diagnosis, remain true today.